Guided Therapeutics and Konica Minolta sign development agreement

Guided Therapeutics or GT, a medical technology company, has entered into an agreement with Konica Minolta Opto, a developer of advanced optical components, to co-develop non-invasive cancer detection products.

The new development agreement follows two years of collaborative preparations to identify large market opportunities that would benefit from GT's proprietary technology.

The new products, for the detection of lung and esophageal cancer, are based on GT's LightTouch non-invasive cervical cancer detection technology, which is undergoing the FDA's premarket approval process.

Mark Faupel, president and CEO of GT, said: "We look forward to working with Konica Minolta to bring these products to market and build upon our cervical cancer detection platform. Our primary focus continues to be completing the FDA process and preparing for launching LightTouch internationally."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: cancer, ceo, market, medical, optical, president, products, technology